U.S. commits to aggressive global TB elimination with mandatory transparency
S. 4751 — End Tuberculosis Now Act of 2026 · Filed by Todd Young (R-IN) · 1 cosponsor · Introduced Jun 11, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the U.S. government to significantly expand foreign aid for tuberculosis prevention, diagnosis, and treatment globally through 2032, with specific goals to reduce TB incidence by 80% and mortality by 90% by 2030. It requires annual reporting on program outcomes, coordinates efforts across federal agencies and international partners, and emphasizes reaching high-risk populations, drug-resistant TB cases, and integrating TB care into broader health systems.
Why we flagged it
The bill is a straightforward authorization for expanded U.S. foreign assistance targeting a specific infectious disease with clear public-health and pandemic-preparedness rationales. It is not a tax measure, appropriation, or regulatory change—it is a policy directive to the executive branch.
What the text implies
- Establishes TB control programs as explicit platforms for pandemic preparedness, potentially expanding U.S. health surveillance and data-sharing infrastructure in partner countries.
- Mandatory annual reporting through 2032 creates sustained congressional oversight and may influence future appropriations decisions on global health spending.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies (TB drug and vaccine developers); diagnostic equipment manufacturers; global health NGOs and implementing partners